New treatment algorithm of mild-to-moderate atopic dermatitis: recommendations for pimecrolimus 1% cream in the topical approach

Article Sidebar

PDF (Język Polski)


Published: Dec 21, 2014
Keywords:
atopic dermatitis, pimercolimus, topical calcineurin inhibitor, topical corticosteroid, treatment algorithm

Main Article Content

Magdalena Czarnecka-Operacz
Katedra i Klinika Dermatologii, Uniwersytet Medyczny im. K. Marcinkowskiego w Poznaniu

Abstract

Treatment of atopic dermatitis (AD) should be individually tailored for patients in relation to the severity and extensiveness of the skin inflammatory process. But there are certain universal rules which are recommended in order to control the disease and reduce the risk of frequent relapses in case of mild-to-moderate course of AD. This paper presents a new treatment algorithm in which pimecrolimus (topical caucineurin inhibitor) is recommended as a first line therapy in case of first signs and symptoms of the disease, after initial treatment with topical corticosteroids (TCSs) as well as maintenance treatment in prevention of subsequent disease flares. These recommendations based on published clinical data have been proposed by Luger et al (Eur J Dermatol, 2013) and widely accepted within the European Union.

Downloads

Download data is not yet available.

Article Details

How to Cite
Czarnecka-Operacz , M. (2014). New treatment algorithm of mild-to-moderate atopic dermatitis: recommendations for pimecrolimus 1% cream in the topical approach. Alergoprofil, 10(4), 5-8. Retrieved from https://journalsmededu.pl/index.php/alergoprofil/article/view/818
Issue
Vol 10 No 4 (2014)
Section
Article

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Akdis C.A., Akdis M., Bieber et al.: Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J. Allergy Clin. Immunol. 2006, 118: 152-169.
2. Darsow U, Wallenberg A, Simon D et al.: EFTAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J. Eur. Acad. Dermatol. Veneorol. 2010, 24: 317-328.
3. Ring J., Alomar A., Bieber T. et al.: Guidelines for treatment of atopic eczema (atopic dermatitis), part I. J. Eur. Acad. Dermatol. Veneorol. 2012, 26: 1045-1060.
4. Bieber T.: Atopic dermatitis. N. Engl. J. Med. 2008, 358: 1483-1494.
5. Odhiambo J.A., Williams H.C., Clayton T.O. et al.: Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J. Allergy Clin. Immunol. 2009, 124: 1251-1258.
6. McKenna S.P., Doward L.C.: Quality of life of children with atopic dermatitis and their families. Curr. Opin. Allergy Clin. Immunol. 2008, 8: 228-231.
7. Watson W., Kapur S.: Atopic dermatitis. Allergy Asthma Clin. Immunol. 2011, 7(supl. 1): S4.
8. Barnetson R.S., Rogers M.: Childhood atopic eczema. BMJ 2002, 324: 1376-1379.
9. Kong H.H., Oh J., Deming C. et al.: Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012, 22: 850-859.
10. Luger T., De Raeve L., Gelmetti C. et al.: Recommendations for Pimecrolimus 1% in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm. Eur. J. Dermatol. 2013, 23(6): 758-766.